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DIRECT EFFECTS OF METFORMIN ON PI3K AND RAS SIGNALING IN
ENDOMETRIAL CANCER
David A. Iglesias, M.D.
Thesis Advisor: Karen H. Lu, M.D.

Metformin has antiproliferative effects through the activation of AMPK and has
gained interest as an antineoplastic agent in several cancer types, although studies
in endometrial cancer (EC) are limited. The aims of this project were to evaluate
pathways targeted by metformin in EC, investigate mechanisms by which metformin
exerts its antiproliferative effects, and explore rational combination therapies with
other targeted agents.
Three EC cell lines were used to evaluate metformin’s effect on cell proliferation,
PI3K and Ras-MAPK signaling, and apoptosis. A xenograft mouse model was also
used to evaluate the effects of metformin treatment on in vivo tumor growth. These
preliminary studies demonstrated that K-Ras mutant cell lines exhibited a decreased
proliferative rate, reduced tumor growth, and increased apoptosis in response to
metformin compared to K-Ras wild-type cells.
To test the hypothesis that mutant K-Ras may predict response to metformin,
murine EC cells with loss of PTEN and expressing mutant K-RasG12D were
transfected to re-express PTEN or have K-Ras silenced using siRNA. While PTEN
expression did not alter response to metformin, cells in which K-Ras was silenced
displayed reduced sensitivity to metformin.
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Mislocalization of K-Ras to the cytoplasm is associated with decreased signaling
and induction of apoptosis.

Metformin’s effect on K-Ras localization was analyzed

by confocal microscopy in cells expressing oncogenic GFP-K-RasG12V. Metformin
demonstrated concentration-dependent mislocalization of K-Ras to the cytoplasm.
Mislocalization of K-Ras to the cytoplasm was confirmed in K-Ras mutant EC cells
(Hec1A) by cell fractionation in response to metformin 1 and 5 mM (p=0.008 and
p=0.004). This effect appears to be AMPK-independent as combined treatment with
Compound C, an AMPK inhibitor, did not alter K-Ras localization. Furthermore,
treatment of EC cells with metformin in combination with PI3K inhibitors resulted in a
significant decrease in proliferation than either agent or metformin alone.
While metformin exerts antineoplastic effects by activation of AMPK and
decreased PI3K signaling, our data suggest that metformin may also disrupt
localization of K-Ras and hence its signaling in an AMPK-independent manner. This
has important implications in defining patients who may benefit from metformin in
combination with other targeted agents, such as mTOR inhibitors.

Copyright © 2012 – David A. Iglesias, MD. All rights reserved.
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1. Introduction
1.1. Overview
Metformin is one of the most widely prescribed oral hypoglycemic agents in the
treatment of type II diabetes mellitus. The American Diabetes Association and the
European Association for the Study of Diabetes both recommend metformin as the
initial pharmacologic therapy for type II diabetes when lifestyle modifications fail (1).
Benefits to its use include that it is generally well tolerated with minimal or rare
adverse effects, cost is low, it is widely available, and is rarely associated with
hypoglycemia.

Recently, the use of metformin has gained interest in cancer

research by demonstrating antineoplastic effects that are independent of its
hypoglycemic effects (2). Furthermore, several clinical studies have demonstrated
the association between metformin and an improvement in cancer incidence and
survival (3-12).

However, there has been limited data on the role of metformin

specifically on endometrial cancer and the studies that have been performed have
been limited to cell culture. As such, we sought to evaluate the effect of metformin
on endometrial cancer in vitro and in vivo and to identify specific genetic alterations
that may make cancer cells more susceptible to metformin treatment.
1.2. History of Metformin
Metformin and other biguanides were derived from guanidine found in Galega
officinalis, otherwise known as goat’s rue or French lilac. This plant was used as a
treatment for polyuria related to diabetes in medieval Europe (13). It was not until
the early 20th century that guanidine was described as the active compound and was
synthesized for widespread use as an oral hypoglycemic agent. Metformin was first
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described in 1922 by Emil Werner and James Bell as a product of the synthesis of
N,N-dimethylguanidine (14).

Previously, in 1918, guanidine was found to

demonstrate hypoglycemic activity in animals (15). Unfortunately, guanidines were
determined to be too toxic and attention shifted to a less toxic extract of G. officinalis
called galegine (isoamylene guanidine) (16).

Galegine and its analogs, the

synthalins, were used sporadically in the 1920s as antidiabetic agents. However, as
a result of the increasing availability of insulin in the 1920s and a better
understanding of the pathophysiology of diabetes, interest in the oral agents waned.
It wasn’t until the 1940s and 50s that guanidines resurfaced primarily as agents to
combat infections. Chloroguanidine hydrochloride was being used in the 1940s as
an antimalarial agent when it was shown to also have a glucose-lowering effect (17).
Around the same time, a prominent Philippine physician named Eusebio Garcia
used a preparation of dimethyl biguanide, which he termed Flumamine, to treat
influenza. He published his report in 1950 and noted that Flumamine was non-toxic
and was associated with a lowering of serum glucose levels (18). Meanwhile, Jean
Sterne, a French physician interested in diabetology, was conducting studies using
galegine in Paris. Based partially on the observations by Eusebio Garcia, Sterne
began exploring the antidiabetic properties of dimethyl biguanide, a compound he
later called “Glucophage” (16). Sterne went on to publish his findings in 1957 (19).
Shortly following this, others published trials with the biguanides phenformin and
buformin (16). Although, both phenformin and buformin were initially considered
more potent than metformin, they quickly fell out of favor due to their higher
association with lactic acidosis and were ultimately discontinued in the 1970s. In
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contrast, metformin became available in the United Kingdom in 1958 and was
approved for use in Canada in 1972. Metformin was not approved by the U.S. Food
and Drug Administration for Type II diabetes mellitus until 1994. Glucophage was
later produced under license by Bristol-Myers Squibb in the U.S. beginning in March
1995. Several generic formulations currently exist.
1.3. Proposed Mechanisms of Metformin Action in Normal and Neoplastic
Tissues
The principle mechanisms of action of metformin in the management of diabetes
mellitus include reducing hepatic gluconeogenesis, increasing insulin sensitivity in
target tissues, and improving glucose uptake by skeletal muscle and adipocytes
(20). These actions ultimately lead to decreased circulating glucose and insulin
levels. Specifically, metformin has been shown to inhibit mitochondrial respiratory
chain complex I resulting in decreased adenosine-5’-triphosphate (ATP) generation
(21), an increase in the AMP to ATP ratio, and subsequent activation of the cellular
energy-sensing liver kinase B-1 (LKB1) and AMP-activated protein kinase (AMPK)
pathway.

AMPK activation results in the

downregulation of energy-consuming

processes such as lipid and protein synthesis in response to energy depletion. In
the case of hepatocytes, this results in a decrease in gluconeogenesis and promotes
glucose uptake. Glucose can be utilized by cells to generate ATP through oxidative
phophorylation or glycolysis. However, following the observations that insulin acts
as a mitogen in a subset of cancer cells (22) and that AMPK activation also inhibits
mammalian target of rapamycin (mTOR) signaling, a pathway involved in cellular
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proliferation and mRNA translation, there has been increasing interest in evaluating
the potential direct antineoplastic effects of metformin.
It has been proposed that metformin exerts its antineoplastic effects through one
or more of three mechanisms, some of which overlap with the mechanisms of action
of metformin in normal tissues (23). In the “indirect” model, the action of metformin
on hepatocytes results in decreased hepatic glucose secretion and increased
glucose uptake. This ultimately leads to decreased circulating glucose and insulin
levels. As insulin acts as a mitogen in a subset of cancers, a reduction in serum
insulin levels may lead to a reduced growth rate of these tumors. However, it has
been proposed that this mechanism would primarily benefit patients with baseline
hyperinsulinemia, tumors that are insulin sensitive, and/or tumors lacking an
activating mutation downstream of the insulin receptor (24).

While metformin’s

activation of the LKB1/AMPK pathway in hepatocytes results in decreased
gluconeogenesis, several early studies also demonstrated that metformin had a
similar “direct” effect on the LKB1/AMPK pathway in cancer cells, including breast,
prostate, colon, and endometrial cancer cell lines. The end product of activation of
LKB1/AMPK in these cells is inhibition of mTOR signaling resulting in decreased
protein synthesis and reduced tumor growth (25-27). Evidence also indicates that
metformin may inhibit growth of certain tumors by causing a cellular “energy crisis.”
In this proposed model, tumors with loss of LKB1 or p53 are unable to sense, and
therefore compensate for, a metformin-induced reduction in ATP resulting in a
continuation of energy-consuming processes that ultimately leads to an energy crisis
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and necrotic cell death (23, 28).

Despite ongoing research, the precise

mechanism(s) of metformin’s antineoplastic activity has yet to be fully defined.
Metformin has also been shown to exhibit cardioprotective effects both in vitro
and in vivo through increasing expression of AMPK and endothelial nitric oxide
synthase (eNOS) and decreasing expression of transforming growth factor (TGF)-β1
in cardiomycotes leading to improved left ventricular function and modeling (29, 30).
Furthermore, metformin use is also associated with a reduction in fatty acid levels
and consequently an improvement in lipid profiles. These actions have translated to
an improvement in survival in a murine model of heart failure (31). In humans, the
United Kingdom Prospective Diabetes Study Group demonstrated that patients with
type II diabetes who used metformin had a 36% decrease in all-cause mortality and
a 39% lower risk of myocardial infarction when compared to other standard
treatments (32). As a result of these findings, there are several ongoing clinical
studies evaluating the role of metformin as a cardioprotective agent (33). These
potential cardioprotective effects may contribute to the improvement in survival seen
in epidemiological studies involving cancer patients.
1.4. Pharmacokinetics of Metformin
The ability of metformin to exert its antidiabetic and antineoplastic effects
depends greatly on the ability of the drug to access and be taken up by the target
tissue. Metformin exists primarily as a hydrophilic cationic molecule at physiologic
pH levels resulting in low lipid solubility and very limited passive diffusion through
cell membranes (34).

As a result, uptake of metformin is largely mediated by

organic cation transporters (OCTs), which are briefly reviewed below. Metformin is
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predominantly absorbed from the small intestine through the activity of several
transporters, notably the plasma membrane monoamine transporter (PMAT) which
is found on the luminal surface of enterocytes (35). Peak plasma concentrations of
metformin occur approximately 3 hours after a single oral dose of an immediaterelease tablet (36).

After multiple doses of 1000 mg twice daily, mean plasma

concentrations of metformin range between 0.4 and 1.3 mg/L (37). The mean halflife is 5.1 hours in healthy patients with adequate renal function (37). The mean
bioavailability of metformin has been estimated as 55+/-16% (34); however, there
appears to be some inter-subject variability which may be a result of differences in
expression levels of transporters.

Once in the circulation, metformin remains

unbound to plasma proteins and has a large volume of distribution (estimated at
approximately 300 L following 2000 mg daily dosing) likely attributable to
considerable tissue uptake of the drug.

Of note, in animal models, metformin

concentrations several-fold higher than serum concentrations have been found in
various tissue types (38, 39).

The primary mode of elimination of metformin is

through renal excretion of unchanged drug. As a result, the elimination of metformin
decreases with worsening renal function. The estimated mean renal clearance is
507+/-129 mL/min in healthy subjects with adequate renal function (34). Although
approximately 20-30% of metformin is recovered in the feces following oral
administration, this appears to be drug that was unabsorbed.

Gastrointestinal

elimination appears to be negligible as no drug has been found in feces following
intravenous administration (36).
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Transport of metformin from the plasma into target tissues is mediated by the
activity of several OCTs, most notably OCT1 and OCT3. Both of these OCTs are
found in many tissues and expressed at varying levels. As a major site of metformin
activity, hepatocytes express high levels of both OCT1 and OCT3 (40). Supporting
the importance of these transporters for metformin action, OCT1-knockout mice
demonstrate decreased hepatic uptake of drug (41).

Furthermore, transient

silencing of OCT1 using siRNA decreased the sensitivity of epithelial ovarian cancer
cells to metformin treatment (42).

Animal studies have demonstrated that while

OCT1 is primarily expressed in the liver, kidney, and small intestine it may also be
expressed in other tissues to a lesser degree (40). In contrast, OCT3 appears to be
strongly expressed in tissues of the female reproductive tract, notably the ovaries,
placenta, and uterus (43).

The high expression of OCTs in the kidneys likely

explains their role in the elimination of metformin. Importantly, other basic drugs,
such as cimetidine and certain antihistamines that are substrates for cation
transporters, may decrease the renal clearance of metformin and vice versa.
1.5. Toxicities and Adverse Effects of Metformin
The most frequently reported adverse effects associated with metformin use are
gastrointestinal and include bloating, flatus, and diarrhea. It is recommended that
metformin be taken with food and initially administered at a low dose and titrated up
to minimize these adverse effects. The most severe and life-threatening adverse
effect associated with metformin is lactic acidosis. Prevention and early diagnosis
and intervention of this condition is essential as it carries a mortality rate of up to
50% (34).

While lactic acidosis was most frequently associated with the older
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generation of biguanides (phenformin and buformin) resulting in their removal from
the market in the 1970s, this warning has remained for metformin. Fortunately, this
complication is rare with an incidence estimated at 3.3 cases per 100,000 patientyears of treatment (44). Interestingly, to put this into perspective, the estimated
incidence of lactic acidosis in sulfonylurea-users is 4.8 cases per 100,000 patientyears (44). However, despite this low risk, it is recommended that therapeutic serum
concentration of metformin not exceed 2.5 mg/L and that metformin doses be
adjusted for renal impairment (34).
1.6. Metformin and the Phosphatidylinositol 3-Kinase (PI3K) Pathway
To better understand the role that metformin may play as an inhibitor of tumor
cell proliferation, we must first understand the pathways involved in its mechanism of
action. Disruption of the PI3K-AKT pathway is considered central to the role of
metformin in both normal and neoplastic tissues. The PI3K pathway is a signal
transduction pathway critical to a variety of cellular functions including cell
proliferation and protein synthesis, cell survival, cell cycle progression, cellular
metabolism, and angiogenesis.

PI3Ks are a family of lipid kinases that function by

phosphorylating the 3-hydroxyl group of phosphoinositides. There are three distinct
classes of PI3Ks that are differentiated by their substrate specificity and regulation
(45). Here we will focus on Class IA PI3Ks as these are the best described and
most commonly implicated in human cancers (46).
Class IA PI3Ks are heterodimers consisting of a p110 catalytic subunit (of which
there are three – p110α, p110β, and p110δ) and a p85 regulatory subunit. While
both p110α and p110β are ubiquitously expressed and are involved in cellular
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proliferation and insulin signaling, p110δ is primarily expressed on leukocytes and
plays a role in immune function. At baseline, p85 binds to the N-terminus of the
p110 subunit inhibiting its catalytic activity (47). Activation of Class IA PI3Ks can
occur through one of several mechanisms.

The typical initiating event in the

activation is the binding of a growth factor ligand (e.g., epidermal growth factor
(EGF), platelet-derived growth factor (PDGF), insulin-like growth factor-1 (IGF-1),
insulin, etc.) to its receptor tyrosine kinase (RTK). This promotes dimerization of the
receptor and autophosphorylation of tyrosine residues.

Following this, p85 is

recruited to the plasma membrane and binds either directly or indirectly, through
adaptor proteins such as insulin receptor substrate-1 (IRS1) or GRB2-associated
binder (GAB), with the RTK releasing its inhibition of the p110 catalytic subunit.
PI3K can also be activated via Ras, which directly activates the p110 subunit
independently of p85 (48).

Of note, the PI3K pathway is one of the best

characterized downstream effectors of Ras and plays an important role in Rasmediated cell survival. The interplay between the Ras-Mitogen Activated Protein
Kinase (Ras-MAPK) and PI3K pathways is reviewed in further detail below.
Activation of PI3K generates phosphatidylinositol 3,4,5-triphosphate (PIP3) from
phosphatidylinositol 4,5-biphosphate (PIP2), a process that is negatively regulated
by the tumor suppressor phosphatase and tensin homolog (PTEN) through its lipid
phosphatase activity, converting PIP3 back to PIP2. Loss of PTEN function, either by
mutation or epigenetic silencing, results in uncontrolled PI3K activity which may
ultimately lead to cancer.

As we will see later, this is clinically important in

endometrial cancer, which has a high frequency of cases with PTEN loss. PIP 3
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recruits the serine-threonine kinase, AKT, to the plasma membrane. Docking of the
pleckstrin homology (PH) domain of AKT to PIP3 induces a conformational change in
AKT exposing two amino-acid residues (T308 and S473) that must be
phosphorylated for full activation of AKT.

Phosphorylation of these residues is

accomplished by 3-phosphoinositide-dependent protein kinase 1 (PDPK1) and the
mTOR-rictor (rapamycin insensitive companion of mTOR) complex (mTORC2),
respectively (49-51). Once AKT is fully activated it acts as a central node in the
PI3K pathway, regulating a wide variety of cellular processes involved with cell
survival, protein synthesis and proliferation, and cellular metabolism (52). One of
the key downstream effectors by which AKT regulates protein synthesis is through
the tuberous sclerosis 1/2 (TSC1/2) complex.

AKT inactivates TSC1/2 which

releases its inhibition on the mTOR-regulatory-associated protein of mTOR (Raptor)
(mTORC1) complex.

The mTORC1 complex propagates the growth signal by

phosphorylating eukaryotic initiation factor 4E-binding protein (4E-BP) and p70
ribosomal S6 kinase (p70S6K) which promote ribosome biogenesis and protein
synthesis. At baseline, this process is also regulated by another variable – the
energy status of the cell. That is, at times of energy deprivation, there is an increase
in the intracellular concentration of AMP relative to ATP. This increase in the ratio of
AMP to ATP activates the cellular energy sensor AMPK. Activated AMPK, in an
attempt to maintain cellular energy homeostasis, then phosphorylates TSC2
resulting in inhibition of mTORC1 signaling which down-regulates energy consuming
processes such as protein synthesis. This is where metformin is believed to have its
predominant direct effect on inhibition of cellular proliferation. As described above,
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metformin inhibits mitochondrial respiratory chain complex I resulting in decreased
ATP production, leading to an increase in the ratio of intracellular AMP to ATP,
activation of AMPK, and ultimately to decreased mTORC1 signaling and decreased
cellular proliferation.
1.7. Ras Activation and the MAPK Pathway
The Ras-MAPK and PI3K-AKT pathways are two of the best characterized
intracellular signaling pathways.

When first discovered, both of these pathways

were thought to be linear pathways that existed in parallel and were even activated
by different stimuli.

However, as they have been further investigated and

characterized, it is clear now that there is a high degree of cross-talk between both
pathways. Ras has been shown to interact with the different isoforms of class IA
PI3Ks (53-55). As such, to understand the role of Ras on PI3K signaling, we must
first understand how Ras is regulated and activated.

Ras proteins are GTPase

binary molecular switches that regulate cell proliferation, differentiation, and survival.
Four distinct Ras isoforms exist – H-Ras, N-Ras, K-Ras4A, and K-Ras4B - which
exhibit a high degree of sequence homology in approximately the first 169 amino
acids (56). The final 23-24 amino acids comprise what is termed the hypervariable
region (HVR) that defines the isoform and contains the membrane interacting and
targeting sequences (56). All Ras isoforms contain a carboxy terminal –CAAX motif,
where C represents cysteine, A is usually an aliphatic amino acid, and X is any
amino acid. This –CAAX motif directs a series of post-translational modifications
that are necessary for activation and trafficking of the Ras protein to the inner leaflet
of the plasma membrane which is required for signaling.
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Newly synthesized Ras proteins immediately undergo a series of posttranslational modifications, some of which are constitutive and irreversible and
others that are conditional and reversible (57).

First, -CAAX is constitutively

processed and modified by three enzymes that appear to work in series resulting in
polyisoprenylation, endoproteolysis, and carboxyl methylation (58). The end result is
that the otherwise hydrophilic Ras proteins become hydrophobic at their C termini
allowing them to associate with intracellular membranes. Indeed, endoproteolysis
and carboxyl methylation are both accomplished on the cytoplasmic surface of the
endoplasmic reticulum and Golgi apparatus (58). Once there, a “second signal” is
required

for trafficking of

endomembranes (56, 59).

Ras

proteins to

the

plasma membrane from

In the case of H-Ras, N-Ras, and K-Ras4A,

palmitoylation of the HVR facilitates this translocation (60, 61).

This process is

dynamic in which depalmitoylation of H-Ras, N-Ras, and K-Ras4A mediates
retrograde transport to the Golgi (62). For K-Ras4B (which will be referred to as
simply K-Ras), the “second signal” has not yet been clearly defined, but is believed
to involve diffusion down an electrostatic gradient involving the polybasic domain of
the HVR (57, 59). That is, the net negative charge of the plasma membrane attracts
the positively-charged polybasic domain of K-Ras. While K-Ras is predominantly
distributed at the plasma membrane, studies have demonstrated that its association
with the plasma membrane is also reversible and dynamic (63).
At the plasma membrane, in the basal state, GDP-bound Ras is inactive. Upon
binding of growth factor ligands to their RTKs, guanine nucleotide exchange factors
(GEFs), such as Son of Sevenless (SOS), are recruited to the plasma membrane by
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GRB2 which activate Ras by promoting the release of GDP and allowing GTP
binding.

Activated Ras can then interact with Ras-binding domains (RBDs) on

effector molecules, including PI3K among others. As is apparent, this process is
similar to, and indeed involves the same growth factors as, that involved in activation
of PI3K. The principal effector pathway of Ras is the MAPK pathway. This kinase
cascade consists of a GTPase-regulated Ras that phosphorylates and activates
RAF kinase which, in turn, phosphorylates and activates MEK which then
phosphorylates and activates the effector kinase, extracellular-signal-related kinase1/2 (ERK1/2). ERK1/2 is involved in promoting cell survival and proliferation and cell
motility (52).

However, constitutive activation of Ras as a result of oncogenic

mutations may also lead to uncontrolled activation of the PI3K pathway which results
in persistent pro-proliferative and pro-survival signaling regardless of the presence of
growth factors. Ras activation is negatively regulated by GTPase-activating proteins
(GAPs) which catalyze GTP hydrolysis to return Ras to the GDP-bound inactive
state (57). Loss of GAPs is another mechanism by which Ras proteins may be
constitutively activated. In the next section we will review the importance of RASPI3K interactions as it pertains to oncogenic signaling.
1.8. The Interaction Between Ras and PI3K in Tumorigenesis
Several

authors

have

commented

and

provided

preclinical

evidence

demonstrating the importance of PI3K in Ras-dependent oncogenic transformation
(64-66). An overview of the key players in these pathways is demonstrated in Figure
1.
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Figure 1. Overview of the PI3K and Ras-MAPK Pathways

It is also well accepted that Ras plays a critical role in both tumor initiation and
maintenance. However, given the presence of multiple Ras effector pathways, it is
important to identify what role each plays in Ras-dependent tumorigenesis. What is
now known is that multiple effector pathways (MAPK, PI3K, and RalGEF) play
critical roles in Ras-dependent tumor initiation.

However, as tumorigenesis

progresses, maintenance of Ras-dependent tumor growth seems to specifically
require PI3K pathway activation (67). Both pathways appear to be highly integrated
with mechanisms of cross-talk including cross-inhibition and cross-activation (52).
The Ras-MAPK and PI3K-AKT pathways can negatively regulate each other. As a
result, inhibition of one pathway may lead to activation of the other such as seen
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with MEK inhibitors and AKT activation (68, 69). Cross-activation can also occur at
several points. As described above, Ras-GTP can directly bind and allosterically
activate PI3K.

ERK1/2 which is downstream on the Ras-MAPK pathway can

activate mTORC1 both indirectly by inhibiting TSC2 (70) at sites different than AKT
which releases its inhibition and promotes mTORC1 activation and directly by
phosphorylating Raptor (71). The clinical importance of this extensive cross-talk,
particularly in endometrial cancer where these pathways are both frequently
mutated, is the obvious need to target more than one pathway to inhibit cancer cell
proliferation and tumor growth. Indeed, this need for dual pathway inhibition has
been demonstrated by human cancer cells carrying alterations in the PI3K pathway
which were responsive to the mTORC1 inhibitor RAD001, except when K-Ras
mutations occurred concomitantly (72). Furthermore, in this same study, in a cohort
of metastatic cancer patients, the presence of oncogenic K-Ras mutations was
associated with lack of benefit after RAD001 therapy (72). Several authors have
demonstrated that inhibition of both PI3K and Ras-MAPK pathways results in
inhibition of tumor growth in prostate and lung cancer mouse models (73, 74) and of
cellular proliferation in human cancer cell lines (75). However, these combination
strategies may be limited in human studies secondary to dose-limiting toxicities.
Thus, it is important to evaluate the role of more tolerable agents, such as
metformin, as a potential component of a targeted combination therapeutic strategy.
This is particularly important in endometrial cancer where both of these tumorigenic
pathways are commonly aberrant.
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1.9. Endometrial Cancer and Metformin
The importance of identifying novel therapeutic strategies for endometrial cancer
is warranted due to its stable, if not increasing, incidence as a result of the growing
worldwide obesity pandemic and associated medical comorbidities, which increase a
woman’s risk of developing the disease. Endometrial cancer is currently the most
common gynecologic malignancy in the United States with an estimated 46,470
women diagnosed with uterine cancer and 8,120 estimated to have died of the
disease in 2011 (76). Based on epidemiological and molecular factors, endometrial
cancer can be subdivided broadly into two types which have important implications
on prognosis and treatment options.

Type I endometrial cancers account for

approximately 80% of cases, are classically of endometrioid histology, and are
associated with obesity and prolonged estrogen stimulation. Type II carcinomas are
often of non-endometrioid histology, typically arise in a background of atrophic
endometrium, and appear to be unrelated to estrogen stimulation. Obesity is an
important risk factor for the development of endometrial cancer. The relative risk of
uterine cancer-related death for women considered obese is 2.53, while for morbidly
obese women it is 6.25 (77). Furthermore, the association between obesity and
other medical co-morbidities, such as diabetes mellitus and insulin resistance, also
contributes to mortality. The prevalence of diabetes in the general population is
approximately 7% to 8% and continues to rise (78).
Type I and Type II ECs frequently demonstrate distinct molecular alterations that
may serve to guide therapeutic treatment strategies. A summary of common genetic
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alterations associated with Type I and Type II endometrial carcinomas is found in
Table 1.

Type I lesions
(%)

Type II lesions
(%)

References

PTEN loss of function

83

10

(79, 84)

PIK3CA mutation

36

5

(81, 86, 87)

Microsatellite Instability

20-30

0-11

(82, 87-89)

K-Ras mutation

15-26

0-5

(83, 84, 90)

β-catenin mutation

25-38

3

(86, 91)

p53 loss of function

10-17

93

(84, 92)

HER-2/neu
overexpression

10

43

(87, 93)

p16 inactivation

10

45

(87, 92)

Genetic Alteration

Table 1. Genetic alterations associated with Type I and Type II endometrial
carcinomas

The most common genetic alteration associated with Type I lesions is a loss of
function of PTEN which can be encountered in up to 83% of cases and 55% of
precancerous lesions (79).

Mutations in PTEN have been documented in

endometrial hyperplasia and, thus, have been suspected to be an early event in the
endometrial tumorigenesis process (80). As described above, PTEN plays a role in
the

regulation

of

the

PI3K-AKT

pathway

by

inhibiting

the

downstream

phosphorylation of AKT, but its loss of function has also has been shown to result in
genomic instability by causing defects in either homologous recombination DNA
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repair or in cell cycle checkpoints. Mutations on PIK3CA, the gene coding for the
catalytic subunit of PI3K, are seen in up to 36% of endometrioid cancers (81) and
are often found in combination with PTEN mutations.
Other common genetic alterations associated with type I endometrial carcinomas
include: microsatellite instability (MSI) and mutations in K-Ras. Approximately 20%
to 30% of type I lesions exhibit MSI (82). Activating mutations in K-ras are observed
in 15-26% of endometrioid carcinomas (83, 84). Although, Ras and PI3K pathway
mutations are found to be mutually exclusive in other cancer types, in endometrial
cancer, tumors with mutations in both pathways often coexist (48). In fact, up to
80% of tumors with a PIK3CA mutation also harbor a K-Ras and/or PTEN mutation
(85). In contrast to Type I lesions, the genetic alteration most commonly seen in
type II lesions is a p53 mutation, which is found in up to 90% of serous carcinomas
(compared with 10% of type I lesions), and PTEN mutations are less common (84).
The frequency of potentially targetable genetic alterations associated with
endometrial carcinomas has resulted in considerable interest in novel therapeutic
strategies for this malignancy.
As described above, metformin is one of the most commonly used hypoglycemic
agents in the management of type II diabetes mellitus, which is associated with
insulin resistance and an increased risk for the development of endometrial cancer.
Several epidemiological studies have demonstrated that diabetic patients being
treated with metformin have a reduced cancer incidence or improved response to
chemotherapy when compared to diabetic patients receiving other oral hypoglycemic
agents or insulin (78, 94, 95). DeCensi and colleagues completed a meta-analysis
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of five observational studies of all cancer types and found that metformin was
associated with a 31% decrease in CA risk (SRR 0.69, 95%CI 0.61-0.79) (95). In a
study of 2,529 patients who received neoadjuvant chemotherapy for early-stage
breast cancer, Jiralerspong and colleagues, reported that the rate of pathologic
complete responses was 24% among diabetic patients using metformin compared
with 8% for diabetic patients not using metformin (p<0.007) (78). While the effects of
metformin on hepatocytes, skeletal muscle, and adipocyte metabolism are
understood, the mechanisms by which metformin exerts these antineoplastic effects,
have not yet been fully characterized.
Given the prevalence of PI3K-AKT pathway alterations associated with
endometrial cancer and its frequent association with obesity and diabetes mellitus,
this is a logical site in which to evaluate the role of metformin as a cancer
therapeutic. However, to date, published reports on the effects of metformin on
endometrial cancer are limited.

In a study evaluating the pre-clinical effects of

metformin, Cantrell and colleagues, using two endometrial cancer cell lines,
demonstrated that metformin was a potent inhibitor of endometrial cancer cell
proliferation that was partially mediated by activation of AMPK with a subsequent
decrease in mTOR signaling (27). Furthermore, the addition of metform to paclitaxel
demonstrated significant synergistic anti-proliferative effects through modulation of
the mTOR signaling pathway (96). However, all cell lines used in both of these
studies expressed functional PTEN. Because metformin is postulated to mediate its
anti-neoplastic effects through activation of AMPK in opposition to PI3K
hyperactivation and given the frequency with which PTEN loss occurs in endometrial
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cancer, our objective was to evaluate and compare the effect of metformin on PTEN
deficient versus PTEN wild-type endometrial cancer in vitro and in vivo.
In addition to alterations in PTEN, K-ras mutations represent another common
genetic defect found in endometrial cancers. Activating mutations in K-ras have
been shown in a mouse model to synergize with PTEN inactivation to accelerate
tumorigenesis in both endometrial (97) and lung cancer (98). In light of the growing
interest in personalized cancer therapy using biologic agents to target specific
molecular pathways, we further sought to characterize the effects of metformin on
endometrial tumors in which K-Ras is activated, either in isolation or accompanied
by loss of PTEN.
The identification of differential responses to metformin based on the genetic
fingerprint of individual endometrial tumors may have important implications in
defining a subset of patients that will benefit from metformin therapy either alone or
in combination with other targeted agents. Furthermore, an understanding of the
molecular mechanisms underlying metformin’s antiproliferative effect should lead to
the development of novel combination therapies for the more effective treatment of a
variety of cancers
2. Methods
2.1. Cell Culture
Hec1A, a well-differentiated human endometrial carcinoma cell line that
expresses PTEN and harbors an activating K-Ras mutation were purchased from
the American Type Culture Collection (ATCC, Manassas, VA). Hec1A cells were
cultured in McCoy’s 5A Modified Medium supplemented with 10% fetal bovine serum
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(FBS), 10,000 U/mL penicillin and 10,000 mcg/mL streptomycin. Ishikawa, a welldifferentiated human endometrial carcinoma cell line with loss of PTEN expression
and wild-type K-Ras was purchased from the European Collection of Cell Cultures
(ECACC, Porton Down, United Kingdom).

Ishikawa cells were cultured in

Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS, 2 mM
L-glutamine, 1 mM sodium pyruvate, 0.1 M non-essential amino acids, 10,000 U/ml
penicillin and 10,000 ug/ml streptomycin. MecPK, a mouse endometrial carcinoma
cell line was derived and immortalized from the endometrial tumor of a transgenic
mouse with homozygous PTEN deletion and a K-Ras mutation (PTEN-/-K-RasG12D)
(97) and was cultured in RPMI 1640 supplemented with 10% FBS and 10,000 U/mL
penicillin and 10,000 ug/mL streptomycin. Cells were incubated at 37oC under 5%
CO2 to 70% confluence before treatment.
2.2. Reagents and Inhibitors
Metformin (1,1-Dimethylbiguanide hydrochloride) was purchased from Sigma
(St. Louis, MO) and dissolved in sterile PBS. BEZ235 (a dual inhibitor of pan-PI3K
and mTOR) and RAD001 (an inhibitor of mTORC1) were purchased from Selleck
Chemicals (Houston, TX) and dissolved in sterile dimethyl sulfoxide (DMSO).
AZD6244 (a MEK inhibitor) was graciously provided by the lab of Dr. Kwong K.
Wong at the University of Texas, M.D. Anderson Cancer Center.
2.3. Metformin Treatment Cell Viability Assays
To evaluate the effect of metformin on endometrial cancer cells in vitro, cell
viability assays were performed. For all cell viability assays, endometrial cancer
cells were seeded in 96-well plates at a density of 4 x 103 cells/well and were
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incubated at 37oC under 5% CO2 for 24 hours prior to drug treatment. The medium
was then replaced with fresh antibiotic-free medium containing metformin at
concentrations ranging from 0.5 – 20 mM. After treatment for 48 hours, cells were
incubated for 3.5 hours with MTT (3-(5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) dye at 37oC under 5% CO2. Following the incubation, the MTT reaction
was halted with the addition of solvent containing 2-propanol, 0.1% NP40, and 4 mM
HCL. Following the addition of MTT solvent, 96-well plates were shaken gently in
the dark for 15 minutes. The absorbance of the purple formazan product catalyzed
by metabolically active cells was recorded at a wavelength of 590nm with 620nm as
a background. The change in the optical density (ΔOD) measured at these two
wavelengths was calculated.

Data are expressed as the relative absorbance

normalized to control PBS-treated cells. Three independent assays were performed
in triplicate.
2.4. Western Blot Analysis Following Metformin Treatment
To evaluate the effect of metformin on protein expression and downstream
signaling in the PI3K and Ras-MAPK pathways, endometrial cancer cells were
seeded on 6-well plates at a density of 2 x 105 cells/well and were incubated at 37oC
under 5% CO2 for 24 hours prior to metformin treatment. The medium was then
replaced with fresh antibiotic-free medium containing metformin at concentrations of
1 mM, 5 mM, and 10 mM for 48 hours. At 48 hours of treatment, the media was
discarded and whole cell lysates were collected with Mammalian Protein Extraction
Reagent (M-PER) (ThermoScientific, Rockford, IL) containing phosphatase inhibitor
(1:100) and protease inhibitor (1:10).
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Protein extraction was accomplished by first discarding the media from each
well. Wells were then washed with sterile PBS. Immediately afterwards, 100 uL of
M-PER, containing protease and phosphatase inhibitors, was added to each well
and incubated on ice at 40C for 30 minutes. Cells were then mechanically lysed with
a spatula and collected into separate, ice-cold 1.5 mL centrifuge tubes. Tubes were
centrifuged at 13,000 rpm for 15 minutes at 4 0C.

Following centrifugation, the

supernatant from each tube was collected and transferred into new, ice-cold 1.5 mL
centrifuge tubes and the cell pellets were discarded.

To calculate the protein

concentration, Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad
Laboratories, Hercules, CA) was mixed with ddH20 at a ratio of 1:4 (total volume
depending on the number of samples). A total of 2 uL of protein sample was added
to 1 mL of dilute protein assay dye into separate cuvettes. Samples were vortexed
thoroughly and allowed to sit at room temperature for 5 minutes before measuring
the absorbance of each sample at 595nm using Bio-Rad SmartSpecTM 3000 (BioRad Laboratories, Hercules, CA).

Concentrations were calculated using the

Bradford formula.
Equal amounts of protein (15 ug) were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) using a 10% gel at 110V. Proteins
were then transferred onto a nitrocellulose membrane using a current of 0.2 amps
over 2.5 hours. Membranes were washed briefly with non-sterile 1X PBS with 20%
Tween-20 (1X PBST) and blocked with 5% nonfat dry milk for 30 minutes and
incubated overnight with gentle shaking at 40C using a 1:1000-2000 dilution of the
primary antibody of interest in 5% nonfat dry milk.

Primary antibodies directed
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against phospho-AMPKα (Thr172), Total AMPK, phospho-Akt (Ser473), Total Akt,
phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), and phospho-S6 ribosomal
protein (Ser235/236) were used. All antibodies were purchased from Cell Signaling
(Beverly, MA) unless otherwise indicated. As a loading control, β-actin expression
was detected using anti-β-actin IgG (Sigma, St. Louis, MO). Following overnight
incubation with primary antibody, membranes were washed thrice for 10 minutes
each using non-sterile 1X PBST and then incubated with a secondary anti-mouse or
anti-rabbit horseradish peroxidase-conjugated antibody (GE Healthcare UK Limited,
Buckinghamshire, United Kingdom) for 1 hour. Secondary antibody was prepared
by adding 3 uL of either anti-mouse or anti-rabbit horseradish peroxidase-conjugated
antibody to 5 mL of ddH20 mixed with an additional 5mL of 5% nonfat dry milk.
Membranes were then washed four times for 15 minutes each in 1X PBST.
Antibody binding was enhanced using SuperSignal® West Dura Extended Duration
Substrate (ThermoScientific, Rockford, IL) and developed. In a similar fashion, the
PTEN and OCT1 expression status for each cell line was determined by western
immunoblotting using primary antibodies directed against PTEN (Cell Signaling,
Beverly, MA) and SLC22A1 (Sigma, St. Louis, MO), respectively.
2.5. Cell Cycle Analysis Following Metformin Treatment
To evaluate the effect of metformin on the cell cycle and apoptosis in
endometrial cancer cells, flow cytometric analysis was performed.

Endometrial

cancer cells were seeded on 6-well plates at a density of 2 x 105 cells/well and were
incubated at 37oC under 5% CO2 for 24 hours prior to metformin treatment. The
cells were then treated with fresh antibiotic-free medium containing metformin at
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concentrations of 1 mM, 5 mM, 10 mM, and 20 mM for 48 hours. After 48 hours,
cells were trypsinized, transferred to separate 15 mL sterile culture tubes, washed in
1X PBS, and centrifuged at 1,500 rpm for 5 minutes. Cells were then resuspended
and fixed in 70% ethanol for a minimum of 24 hours at 4 0C with gentle shaking.
Cells were then centrifuged at 2,500 rpm for 5 min, washed with 1X PBS, and
resuspended in staining solution containing: 40 µg/mL propidium iodide, 80 µg/mL
RNase A in PBS supplemented with 0.1% Triton X-100 and 0.1 mM EDTA. Cells
were incubated in the staining solution at room temperature for 30 minutes before
cell cycle analysis was performed using the Gallios Flow Cytometer (Beckman
Coulter, Indianapolis, IN) according to the manufacturer’s protocol.

Kaluza Flow

Cytometry Analysis v1.1 software (Beckman Coulter) was used to calculate the cell
cycle distribution from the histogram.

Apoptotic cells were determined on the

histogram as the percentage of cells in the sub-G1 peak.
2.6. In Vivo Xenograft Study
To validate our in vitro results in a xenograft mouse model, 60 female athymic
nude mice were purchased from the National Institutes of Health (Bethesda, MD)
and housed at 5 mice per cage in a specific pathogen-free facility. Nude mice were
maintained in accordance with guidelines established by the Institutional Animal
Care and Use Committee.

At 6-weeks of age, intraperitoneal injections were

performed on each mouse in the midline lower abdomen with 5 x 10 6 early-passage
endometrial cancer cells (20 injected with Hec1A cells, 20 injected with Ishikawa
cells, 20 injected with MecPK cells). Tumors were allowed to progress for 7 days
prior to initiating either control or metformin treatment. Each group of 20 mice per
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cell line was divided into two subgroups of 10 mice each. Ten mice were treated
with metformin dissolved in drinking water (5 mg/mL) and the remaining ten mice
were provided untreated sterile drinking water. Both metformin-treated water and
control untreated water were changed twice weekly on Tuesdays and Fridays.
Treatment continued until at least one mouse became moribund, at which time all
animals in the same endometrial cancer cell line group were euthanized. Serum
was collected immediately and was stored at -80oC. Serum from each mouse was
sent for analysis of liver chemistries. Mice were weighed prior to necropsy and all
visible tumor was carefully dissected from all peritoneal surfaces. Tumors were then
weighed, a representative portion of tumor was fixed in formalin, and the remainder
was flash frozen and stored at -80oC.
2.7. Immunohistochemical Analysis of Xenograft Tumor Tissues
Slides were cut from formalin-fixed, paraffin-embedded tissue blocks for both
Hec1A and Ishikawa and were then used for immunohistochemical analysis of tumor
phosphorylated S6 ribosomal protein (pS6rp) expression as a downstream marker of
PI3K/AKT pathway signaling and Ki-67 staining as a marker for proliferation.
Immunohistochemistry staining was carried out by first baking slides in a 60 0C oven
for 30 minutes. Slides were then deparaffinized by washing in xylene thrice for 10
minutes each. Slides were then rehydrated in serial graded ethanol – 100%, 100%,
100%, 80%, 80%, ddH2O for 3 minutes each. Finally, slides were rinsed in 1X PBS
for 5 minutes. Antigen retrieval was accomplished by first placing slides in a citrate
buffer bath (pH 6.0) and bringing the bath to a slow boil. Slides in the citrate buffer
bath were then transferred into a pressure cooker and the temperature increased to
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1200C. Slides were incubated in the pressure cooker at 120 0C for either 9 minutes
(Ki-67) or 11 minutes (pS6rp). At the desired antigen retrieval time, the pressure
cooker was turned off and slides were removed and allowed to cool at room
temperature in the citrate buffer bath for 30-60 minutes. Following antigen retrieval,
slides were submerged in 3% H2O2 for 10 minutes to block endogenous peroxidase
activity. After blocking slides with 1% normal goat serum for 15 minutes, primary
antibody was applied and slides were incubated overnight at 4 0C in a humidified
chamber. The primary antibodies used were phosphorylated S6 ribosomal protein
(S235/236) rabbit monoclonal antibody (Cell Signaling Technology, Beverly, MA) at
1:50 dilution and purified mouse anti-human Ki-67 monoclonal antibody (BD
Biosciences, San Diego, CA) at 1:50 dilution. Following overnight incubation, slides
were washed in 1X PBST twice for 5 minutes to remove the primary antibody.
Slides were then treated with biotin-labeled affinity isolated goat anti-rabbit and goat
anti-mouse immunoglobulins in PBS (DakoCytomation, Carpinteria, CA) for 10
minutes followed by a wash in PBS and then application of streptavidin-horseradish
peroxidase solution (DakoCytomation, Carpinteria, CA) for 10 minutes. Slides were
rinsed in PBS and developed with 3,3’-diaminobenzidine (DakoCytomation,
Carpinteria, CA) for 1 minute and 45 seconds, rinsed in tap water, counterstained in
10% hematoxylin, and dehydrated in serial graded ethanol.
Phosphorylated S6rp expression was scored as the product of the percentage of
cells staining positive (0 = <10%; 1 = 10-25%; 2 = 26-50%, 3 = 51-75%, and 4 =
>75%) and the intensity of the staining (1 = weak; 2 = moderate; 3 = strong). For the
proliferation index, the average of the ratio of positive Ki-67 stained nuclei to total
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nuclei in > 3 representative high-powered fields from each specimen was
determined.
2.8. Transfection of MecPK Cells for Stable Expression of PTEN
To determine whether the expression of PTEN alters the proliferative or cell
viability response to metformin treatment, MecPK cells were transfected to stably
express PTEN. MecPK cells were seeded on 6-well plates at a density of 2 x 105
cells/well and were incubated at 37oC under 5% CO2 for 24 hours. For transfection,
a pIRES2-EGFP plasmid (Clontech Laboratories, Mountain View, CA) was used to
construct a vector with and without PTEN inserted that also contained a
neomycin/kanamycin-resistance domain to allow for stable selection of PTEN
expressing cells. A plasmid lacking a neomycin-resistance domain, pCMV5-FLAGPTEN, from which we obtained the PTEN gene for our plasmid vector was
graciously provided by the lab of Dr. Gordon Mills (University of Texas, M.D.
Anderson Cancer Center).
DH5α competent bacteria were thawed on ice and transformed by incubating
with the pIRES2-EGFP vector diluted 1:10 in sterile ddH2O in vented conical tubes.
During the transformation, bacteria were placed on ice for 30 minutes followed by a
heat shock at 420C for 1 minute to promote plasmid uptake by bacteria. Bacteria
were then placed on ice for an additional 2 minutes prior to adding 1 mL lysogeny
broth (LB) to each tube. Bacteria were then incubated at 37 0C for one hour and then
plated on LB Agar Kanamycin-50 100mm plates (Sigma, St. Louis, MO) and
incubated overnight at 370C.

Following overnight incubation, one colony was

selected from the plate using a sterile toothpick and placed in a vented 15 mL
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conical tube in 3 mL of LB and incubated at 370C for 16 hours with vigorous shaking.
At the completion of the 16 hour incubation, 1 mL of the LB containing transformed
bacteria was transferred into two separate 1.5 mL centrifuge tubes. Bacterial cells
were harvested by centrifugation at 13,000 rpm for 3 minutes at room temperature.
The supernatant was discarded and a QIAprep Spin Miniprep Kit (Qiagen Sciences,
Venlo, Netherlands) was used to purify plasmid DNA per the manufacturer’s
instructions.

The restriction map of pCMV5-FLAG-PTEN demonstrated that the

PTEN gene is flanked by restriction sites for EcoRI and BamHI restriction enzymes
(Promega, Madison, WI). The restriction map of pIRES2-EGFP also demonstrated
that the multiple cloning site contains restriction sites for both EcoRI and BamH1.
Both pIRES2-EGFP and pCMV5-FLAG-PTEN plasmids were independently
digested using a mixture of 10 uL of plasmid DNA, 2 uL 10X E Buffer (Promega,
Madison, WI), 1 uL BamHI, 1 uL EcoRI, and 6 uL of ddH2O and incubated at 370C
for 1 hour. During the last 15 minutes of the digestion for pIRES2-EGFP, 1 uL of
shrimp alkaline phosphatase was added to the mixture to remove the phosphates
and prevent re-annealing. DNA fragments were separated on a 1% agarose gel at
80V for 1 hour. The bands corresponding to PTEN (1.3kb) and linearized pIRES2EGFP (5kb) were cut out and extracted from the gel using the QIAEX II Agarose Gel
Extraction Kit (Qiagen Sciences, Venlo, Netherlands) per the manufacturer’s
instructions. Ligation of the PTEN gene insert into the linearized pIRES2-EGFP
vector was accomplished using a mixture of 4 uL 5X ligase, 4 uL linearized pIRES2EGFP DNA, 4 uL PTEN gene insert DNA, 1 uL T4 ligase, and 7 uL of ddH2O.
Following ligation, DH5α competent bacteria were transformed, using methods
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previously described above, with either pIRES2-EGFP-PTEN, linearized pIRES2EGFP, and ligated pIRES2-EGFP and cultured on LB Agar Kanamycin-50 100mm
plates (Sigma, St. Louis, MO) and incubated overnight at 370C. Colonies were
selected from plates containing bacteria transformed with pIRES2-EGFP-PTEN and
ligated pIRES2-EGFP and transferred to vented conical tubes containing LB with a
1:1000 dilution of kanamycin and incubated at 370C for 16 hours. As expected,
plates seeded with bacteria transformed with linearized pIRES2-EGFP did not
develop colonies resistant to kanamycin.

Plasmid DNA purification using the

QIAprep Spin Miniprep Kit was performed as described above followed by digestion
of plasmid DNA using BamHI and EcoRI restriction enzymes and separation of DNA
fragments on a 1% agarose gel to confirm insertion of PTEN in the pIRES2-EGFPPTEN plasmids and absence of PTEN in the pIRES2-EGFP control plasmids.
For transfection, 4 ug of plasmid DNA was used per well of a 6-well plate and
performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). One day before
transfection, 2 x 105 MecPK cells were plated per well in 2 mL of antibiotic-free RPMI
1640 growth medium supplemented with 10% FBS and incubated at 37 0C overnight
to reach 80-90% confluence at the time of transfection.

One well was transfected

with pIRES2-PTEN, one well with pIRES2 vector alone (as a negative control), one
well with Lipofectamine 2000 alone (mock transfection), and three untransfected
wells without Lipofectamine 2000.

Media containing Lipofectamine 2000 was

replaced after 6 hours with fresh media. After 24 hours, G418-sulfate 750 ug/mL
(Cellgro, Manassas, VA) was applied to the two transfected wells and the mock
transfected well.

Concurrently, a titration experiment using G418-sulfate on
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untransfected MecPK cells found that a concentration of 500 ug/mL to 750 ug/mL
was sufficient to kill all cells within 5-7 days. In transfected wells, media with G418sulfate was replaced every 3 days until resistant colonies were identified.

Five

resistant colonies from each well were selected and expanded. Whole cell lysates
were collected as per the protocol described above and were analyzed for PTEN
expression by western blot analysis. To verify PTEN functionality, expression of
pS6rp, as a downstream read-out of the PI3K pathway, was evaluated.
MecPK cells stably expressing PTEN and negative controls transfected with
pIRES2-EGFP vector alone were seeded in 96-well plates at a density of 4 x 103
cells/well and were incubated at 37oC under 5% CO2 for 24 hours. The medium was
then

replaced

with

fresh

antibiotic-free

medium

containing

metformin

at

concentrations ranging from 0.5 – 20 mM. After treatment for 48 hours, MTT assays
were performed as described above to compare differences in relative cell viability
between MecPK cells expressing PTEN and those with loss of PTEN.

Three

independent assays were performed in triplicate.
2.9. Transient Silencing of K-Ras with siRNA
To determine whether inhibition of mutant K-Ras signaling reduced the inhibitory
effects of metformin on cell proliferation and viability, K-Ras expression was
transiently silenced in MecPK cells using siRNA. MecPK cells were seeded on 96well plates at a density of 4 x 103 cells/well and were incubated at 37oC under 5%
CO2 for 24 hours. Equal numbers of wells were transfected with either siGENOME
SMARTpool K-Ras siRNA (Dharmacon, Lafayette, CO) or siGENOME non–targeting
siRNA (Dharmacon, Lafayette, CO) using RNAiMax (Invitrogen, Carlsbad, CA) as
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per the manufacturer’s protocol. Media was replaced after 6 hours with fresh media
containing increasing concentrations of metformin (0.5 – 20 mM). After treatment for
48 hours, MTT assays were performed as described above to compare differences
in relative cell viability between MecPK cells expressing mutant K-Ras and those
with silenced K-Ras. Three independent assays were performed in triplicate.
2.10. Transfection of Ishikawa Cells for Stable Expression of Oncogenic KRasG12D Mutant
To determine whether expression of mutant K-Ras increased the susceptibility of
a cell to metformin treatment compared to wild-type K-Ras, Ishikawa cells were
transfected to stably express an oncogenic K-RasG12D mutant. Ishikawa cells were
seeded on 6-well plates at a density of 2 x 105 cells/well and were incubated at 37oC
under 5% CO2 for 24 hours. For transfection, a pMEV-2HA plasmid vector (Biomyx
Technology, San Diego, CA) was used with and without oncogenic K-RasG12D
inserted. Plasmids were graciously provided by the lab of Dr. Kwong K. Wong at the
University of Texas, M.D. Anderson Cancer Center. For plasmid DNA transfection,
4 ug of plasmid DNA was used per well of a 6-well plate and performed using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as per the manufacturer’s protocol.
One well was transfected with pMEV-KRAS-G12D, one well with pMEV vector alone
(as a negative control), and one well with Lipofectamine 2000 alone (mock
transfection). Media containing Lipofectamine 2000 was replaced after 6 hours with
fresh media. After 24 hours, G418-sulfate 750 ug/mL was applied to transfected
wells and replaced every 3 days until resistant colonies were identified. All Ishikawa
cells in the mock transfection well were killed within 7 days with G418-sulfate 750
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ug/mL. Five resistant colonies were selected from each well and expanded and
ultimately analyzed for K-Ras expression at the mRNA level by quantitative RTqPCR.
Cells were first trypsinized and transferred to fresh labeled 1.5 mL centrifuge
tubes. Tubes were centrifuged at 500 x g for 10 minutes to pellet the cells and the
supernatant was then discarded. Cell pellets were resuspended in 500 uL of Trizol
reagent (Life Technologies, Carlsbad, CA) followed by the addition of chloroform at a
dilution of 1:5. Samples were vortexed and incubated at room temperature for 15
minutes. Samples were then centrifuged at 13,000 rpm for 15 minutes at 40C. The
upper, aqueous phase containing the RNA was transferred to fresh, ice-cold 1.5 mL
centrifuge tubes. RNA was precipitated by adding 500 uL of 2-propanol to each
sample and incubating overnight at -200C. Following the incubation, samples were
centrifuged at 13,000 rpm for 15 minutes at 40C to pellet the RNA. RNA was then
washed twice in 75% ethanol.

Following centrifugation, the supernatant was

discarded and the RNA pellets were allowed to air-dry at room temperature for 15
minutes. The RNA pellets were then resuspended in approximately 15-30 uL of
DEPC/RNase-free water (Ambion, Carlsbad, CA).

RNA concentrations were

quantified using the Bio-Rad SmartSpecTM 3000 (Bio-Rad Laboratories, Hercules,
CA). Aliquots from each sample were then treated with DNaseI. RT-qPCR using
primers for 18S (Applied Biosystems, Carlsbad, CA) and human KRAS (Applied
Biosystems, Carlsbad, CA) was performed to determine mRNA expression of KRAS
in selected clones. The PCR protocol utilized was as follows: 500C for 10 minutes
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and 950C for 5 minutes, followed by 950C for 12 seconds and 600C for 30 seconds
for 40 cycles.
The clone demonstrating the greatest expression of K-Ras relative to negative
controls was selected for viability assays. Ishikawa cells expressing oncogenic KRasG12D and their corresponding negative controls were seeded in 96-well plates
at a density of 4 x 103 cells/well and were incubated at 37oC under 5% CO2 for 24
hours. The medium was then replaced with fresh antibiotic-free medium containing
metformin at concentrations ranging from 0.5 – 20 mM. After treatment for 48 hours,
MTT assays were performed as described above to compare differences in relative
cell viability between Ishikawa cells expressing the oncogenic K-RasG12D mutant
and those with wild-type K-Ras expression.

Three independent assays were

performed in triplicate.
2.11. Confocal Imaging Analysis of the Effect of Metformin Treatment on
Subcellular K-Ras Localization
As Ras transport to the plasma membrane is critical to its activation and
intracellular signaling, a series of experiments were performed to evaluate the effect
of metformin on Ras localization. Specifically, K-Ras and H-Ras localization was
analyzed by confocal microscopy using Madin-Darby Canine Kidney (MDCK) cells
expressing GFP-labeled oncogenic K-RasG12V or H-RasG12V mutants.

These

experiments were performed in collaboration with the lab of Dr. John Hancock at the
University of Texas – Houston Medical School. MDCK cells were cultured in DMEM
(ThermoScientific, Waltham, MA) supplemented with 10% FBS and 1 mM sodium
pyruvate and plated at a density of 1 x 10 5 cells/well on coverslips in 12-well plates
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and incubated at 370C, 5% CO2 overnight. Cells were treated with vehicle (PBS) or
metformin (0.001 – 2 mM) for 48 hours to allow new protein synthesis and trafficking.
After treatment, cells were fixed with 4% paraformaldehyde at room temperature for
30 minutes and quenched with 50mM ammonium chloride for 10 minutes. Coverslips
were mounted onto slides in Mowiol and imaged by confocal microscopy using a
Nikon A1R Confocal Laser Microscope (Nikon, Tokyo, Japan). Three independent
experiments were performed in which three representative fields from each slide
were imaged and analyzed using ImageJ software. The ratios of membrane-bound
GFP-labeled K-Ras and H-Ras to total (membrane + cytoplasmic) K-Ras and H-Ras
were calculated. A similar experiment was performed in Hec1A cells transfected
with GFP-labeled K-RasG12V and treated with 0.1 to 5 mM of metformin over 48
hours.
2.12. Analysis of the Effect of Metformin Treatment on Subcellular K-Ras
Localization in a Human Endometrial Cancer Cell Line
To confirm and validate the results obtained using confocal microscopy on
human endometrial cancer; subcellular fractionation was carried out in Hec1A cells
to quantify the proportion of membrane-bound K-Ras compared to total K-Ras as a
function of metformin treatment. Hec1A cells were plated at a density of 2 x 10 6
cells per plate on 100mm plates and incubated overnight in antibiotic-free medium at
37oC, 5% CO2. Cells were then treated with vehicle (1X PBS) or metformin (0.1 mM,
0.5 mM, 1 mM, and 5 mM) for 48 hrs. Following treatment, cell fractionation was
performed using a Subcellular Protein Fractionation Kit (ThermoScientific, Waltham,
MA) as per the manufacturer’s protocol to extract the membrane and cytoplasmic
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fractions. Cells were harvested with trypsin-EDTA and separated by treatment into
in different 15 mL conical tubes. Cells were centrifuged at 500 x g for 5 minutes and
the media supernatant was discarded. The cell pellet was resuspended in ice-cold
1X PBS. Cells were counted and a total of 6 x 106 cells from each treatment group
were transferred into separate pre-chilled 1.5 mL centrifuge tubes.

Cells were

centrifuged at 500 x g for 3 minutes. The supernatants were discarded and the cell
pellets were resuspended in 350 uL of cytoplasmic extraction buffer (CEB)
containing a 1:100 dilution of HaltTM Protease Inhibitor Cocktail (ThermoScientific,
Waltham, MA). After adding the CEB to the cell pellet, cells were incubated at 4 0C
for 10 minutes with gentle mixing. Following the incubation, cells were centrifuged at
500 x g for 5 minutes.

The supernatant, representing the cytoplasmic protein

fraction, was immediately transferred to separate pre-chilled 1.5 mL centrifuge tubes
and labeled.

The cell pellet was then resuspended in 350 uL of membrane

extraction buffer (MEB) containing a containing a 1:100 dilution of protease inhibitor,
vortexed vigorously for 5 seconds, and then incubated at 4 0C for 10 minutes with
gentle mixing. Following the incubation, cells were centrifuged at 3000 x g for 5
minutes.

The supernatant, representing the membrane protein fraction, was

immediately transferred to separate pre-chilled 1.5 mL centrifuge tubes and labeled.
Protein concentrations from the membrane and cytoplasmic fractions were
determined as described by the methods above and equal amounts of protein (15
ug) were separated by SDS-PAGE using a 12% gel and transferred onto a
nitrocellulose membrane.
same gel.

Membrane and cytoplasmic fractions were run on the

Rabbit monoclonal Na+/K+ ATPase alpha antibody (Epitomics,
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Burlingame, CA) and total AKT (Cell Signaling, Beverly, MA) were used as loading
controls and to confirm the purity of membrane and cytoplasmic fractions,
respectively. Primary monoclonal anti-c-K-Ras, clone 234-4.2 (Sigma, St. Louis,
MO) was used to evaluate the expression of K-Ras in each cellular fraction.
Densitometry analyses of western immunoblots were carried out using ImageJ
software and the ratio of membrane-bound K-Ras to total (membrane + cytoplasmic)
K-Ras was calculated. Three independent experiments were performed in triplicate.
2.13. Analysis of the Effect of Aminoimidazole-4-Carboxamide Riboside
(AICAR) Treatment on Subcellular K-Ras Localization
AICAR (Cell Signaling, Beverly, MA) is an AMP analog that promotes activation
of AMPK by increasing the ratio or intracellular AMP to ATP. As this is a mechanism
by which metformin is thought to also exert its anti-proliferative effects, we sought to
evaluate whether AMPK activation by AICAR would affect subcellular K-Ras
localization. Hec1A cells were plated at a density of 2 x 10 6 cells per plate on
100mm plates and incubated overnight in antibiotic-free medium at 37oC, 5% CO2.
Cells were then treated with either vehicle (1X PBS), metformin (1 mM and 5 mM),
or AICAR (0.1 mM and 1 mM) for 48 hours. Following treatment, cell fractionation
was performed in a similar manner as described above using a Subcellular Protein
Fractionation Kit (ThermoScientific, Waltham, MA) to extract the membrane and
cytoplasmic fractions. Equal amounts of protein (15 ug) were separated by SDSPAGE using a 12% gel and transferred onto a nitrocellulose membrane. Membrane
and cytoplasmic fractions were run on the same gels. Rabbit monoclonal Na+/K+
ATPase alpha antibody (Epitomics, Burlingame, CA) and total AKT (Cell Signaling,
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Beverly, MA) were again used as loading controls. Primary monoclonal anti-c-KRas, clone 234-4.2 (Sigma, St. Louis, MO) was used to evaluate the expression of
K-Ras in each cellular fraction. Densitometry analysis of western immunoblots was
carried out using ImageJ software and the ratio of membrane-bound K-Ras to total
(membrane + cytoplasmic) K-Ras was calculated. Two independent experiments
were performed in triplicate.
2.14. Analysis of the Effect of Co-Treatment of Compound C, an AMPK
Inhibitor, with Metformin or AICAR on Subcellular K-Ras Localization
To determine whether changes in subcellular K-Ras localization are AMPKdependent, we sought to evaluate whether concurrent treatment with Compound C,
an inhibitor of AMPK, would abrogate the effects seen with either metformin or
AICAR. Hec1A cells were plated at a density of 2 x 10 6 cells per plate on 100mm
plates and incubated overnight in antibiotic-free medium at 37oC, 5% CO2. Cells
were then treated with either DMSO (control), metformin 5 mM +/- Compound C 10
uM, or AICAR 1 mM +/- Compound C 10 uM for 48 hours. Compound C was
administered 1 hour prior to initiating treatment with either metformin or AICAR.
Following 48 hours of treatment, cell fractionation was performed in a similar manner
as described above using a Subcellular Protein Fractionation Kit (ThermoScientific,
Waltham, MA) to extract the membrane and cytoplasmic fractions. Equal amounts
of protein (15 ug) were separated by SDS-PAGE using a 12% gel and transferred
onto a nitrocellulose membrane. Membrane and cytoplasmic fractions were run on
the same gels.

Rabbit monoclonal Na+/K+ ATPase alpha antibody (Epitomics,

Burlingame, CA) and total AKT (Cell Signaling) were again used as loading controls.
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Primary monoclonal anti-c-K-Ras, clone 234-4.2 (Sigma, St. Louis, MO) was used to
evaluate the expression of K-Ras in each cellular fraction. Densitometry analyses of
western immunoblots were carried out using ImageJ software and the ratio of
membrane-bound K-Ras to total (membrane + cytoplasmic) K-Ras was calculated.
Two independent experiments were performed in triplicate.
2.15. Combination of Metformin with PI3K inhibitors or MEK inhibitor
To evaluate the role of metformin in combination with other targeted agents, a
series of MTT viability assays and western immunoblots were performed. MecPK
cells were seeded on 96-well plates at a density of 4 x 103 cells/well and incubated
at 37oC under 5% CO2 for 24 hours. Cells were treated with either DMSO (control),
metformin alone (1, 5, and 10 mM), an mTOR inhibitor alone (RAD001 10 and 30
nM), a dual inhibitor of pan-PI3K and mTOR alone (BEZ235 100 and 500 nM), a
MEK inhibitor alone (AZD6244 2 and 10 uM), or the combination of each targeted
biologic agent with metformin.

After 48 hours of treatment, MTT assays were

performed as described above to compare differences in relative cell viability
between each drug alone or different combinations at their approximate half maximal
inhibitory concentration (IC50). Three independent experiments were performed in
triplicate.
To evaluate the effect of combination therapies on the PI3K and Ras-MAPK
signaling pathways, MecPK cells were seeded on 6-well plates at a density of 3 x
105 cells/well and were incubated at 37oC under 5% CO2 for 24 hours. Cells were
then treated with either DMSO, metformin 5 mM alone, RAD001 10 nM alone,
AZD6244 6 uM alone, or the combination of RAD001 10 nM plus metformin 5 mM or
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RAD001 10 nM plus AZD6244 6 uM. Cells were treated for 48 hours after which
whole cell lysates were harvested and total protein concentrations were calculated
as described above. Equal amounts of protein (15 ug) were separated by SDSPAGE using 10% gels and then transferred onto a nitrocellulose membranes.
Membranes were incubated overnight at 40C with 1:1000 dilutions of primary
antibodies directed against phospho-AMPKα (Thr172), Total AMPK, phospho-Akt
(Ser473), Total Akt, phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), and phosphoS6 ribosomal protein (Ser235/236) - all purchased from Cell Signaling (Beverly, MA).
β-actin expression served as a loading control and was detected using anti-β-actin
IgG (Sigma, St. Louis, MO). Three independent experiments were performed.

A

similar experiment treating MecPK cells with either DMSO, BEZ235 250 nM alone,
metformin 5 mM alone, metformin 10 mM, and the combination of BEZ235 250 nM
with either metformin at 5 mM or 10 mM was also completed.
2.16. Statistical Analyses
The values obtained are presented as the mean + SEM and analyzed using the
Student’s t-test or the Mann-Whitney U test (GraphPad Prism, version 5). Doseresponse curves were converted into logarithmic curves and IC50 values calculated
using GraphPad Prism, version 5 software. For all results, significance was set as p
< 0.05.

The data presented are the results of three independent experiments

performed in triplicate unless otherwise indicated.
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3. Results
3.1. Metformin

Significantly

Inhibits

Proliferation

of

K-Ras

Mutant

Endometrial Cancer Cell Lines
To study the effects of metformin on endometrial cancer cell viability and
proliferation, Hec1A, Ishikawa, and MecPK cells were treated with various
concentrations (0.5–20 mM) of metformin over 48 hours. Metformin significantly
inhibited the relative viability of MecPK and Hec1A cells in a concentrationdependent manner with a significant decrease in relative cell viability achieved at
concentrations of 0.5 mM (p=0.008) and 5 mM (p<0.001), respectively. The mean
IC50 was 1.16 mM for MecPK cells and 4.23 mM for Hec1A (Figure 2). In contrast,
Ishikawa cell proliferation was significantly inhibited only at the highest metformin
concentration (20 mM, p=0.015) and the IC50 could not be calculated based on the
concentrations of metformin administered.

Figure 2. Log-scale dose-response curves for metformin treatment over 48h in
Hec1A, Ishikawa, and MecPK cells. Metformin causes a significant concentrationdependent decrease in relative survival in both MecPK and Hec1A. In contrast, in
Ishikawa cells, a significant decrease in relative cell viability was seen only at the
highest concentration used (20mM). These data represent three independent
experiments performed in triplicate. Error bars indicate +/- SEM.
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3.2. Effect of Metformin on Expression of AMPK, PI3K-AKT and Ras-MAPK
Pathways
To investigate the effect of metformin on AMPK and on downstream signaling
through the PI3K-AKT and Ras-MAPK pathways, we treated Hec1A, Ishikawa, and
MecPK cells with metformin (1–10 mM) over 48 hours (Figure 3A). Immunoblotting
demonstrated that Hec1A cells expressed PTEN while Ishikawa and MecPK cells
had lack of PTEN expression and all cell lines expressed OCT1 (Figure 3B).

Figure 3. Western immunoblots following metformin treatment - A) Protein
expression following metformin treatment after 48 h. In all cell lines, there is an
concentration-dependent increase in AMPK activation with metformin treatment.
There is a concentration-dependent decrease in pS6rp and pERK1/2 expression in
both K-Ras mutant cell lines (Hec1A and MecPK), but not in K-Ras wild-type
Ishikawa cells. B) PTEN is expressed in Hec1A cells, but not in Ishikawa and
MecPK. All cell lines express the organic cation transporter-1 (OCT1) that is required
for metformin transport into cells.
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Metformin induced phosphorylation of AMPK in a concentration-dependent
manner in all cell lines.

We next evaluated the effect on metformin on the

downstream target of the mTOR pathway, the S6 ribosomal protein (S6rp). While
metformin treatment resulted in a concentration-dependent decrease in pS6rp
expression in Hec1A and MecPK cells, pS6rp expression was not affected by
metformin in Ishikawa cells even at high (10 mM) concentrations.

ERK1/2 are

downstream targets of the Ras-MAPK pathway. Similar to the effect seen on S6rp,
metformin induced a concentration-dependent decrease in phosphorylation of
ERK1/2 in Hec1A and MecPK cells, but not in Ishikawa cells indicating that
metformin may have an effect on Ras-MAPK signaling in K-Ras mutant cells.
Although AKT is upstream of TSC-2 (the direct target of AMPK), metformin
treatment resulted in decreased phosphorylation of AKT in both Hec1A and MecPK
cells indicating that metformin may also have effects upstream in the PI3K pathway
possibly independent of its activity through AMPK.
Ishikawa cells.

This effect was not seen in

Total AKT and total AMPK expression were not affected by

metformin in any of the cell lines tested.

3.3. Effect of Metformin on Apoptosis and Cell Cycle Progression
To determine the effect of metformin on apoptosis we evaluated the fraction of
cells in the sub-G1 phase as a function of metformin treatment using flow cytometry
(Figure 4A). Metformin appears to be a potent inducer of apoptosis in Hec1A and
MecPK cells with significant increases in the fraction of apoptotic cells seen at
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concentrations of 5 mM (p<0.001) and 1 mM (p=0.048), respectively. In contrast,
metformin did not induce apoptosis in Ishikawa cells.
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Figure 4. Cell cycle analysis following metformin treatment - A) The
proportion of cells in the sub-GI phase following 48h of metformin treatment at
increasing concentrations, normalized to control. Metformin significantly induces
apoptosis in both Hec1A and MecPK at concentrations as low as 5mM and 1mM,
respectively. Metformin does not induce apoptosis in Ishikawa cells. B) The ratio
of cells in the G1 phase to G2 phase following 48h of metformin treatment at
increasing concentrations, normalized to control. While metformin induced a G1
cell cycle arrest in Ishikawa cells at the highest metformin concentration, it
induced a concentration-dependent G2/M arrest in MecPK cells. Metformin did
not produce a cell cycle arrest in Hec1A cells. These data represent three
independent experiments. Error bars indicate +/- SEM.
We also evaluated the effect of metformin treatment on the cell cycle by
comparing the ratio of cells in the G1:G2 phase as a function of metformin treatment
(Figure 4B). Metformin induces a G2/M arrest in MecPK cells at concentrations as
low as 5 mM (p<0.001). In contrast, metformin induces a G1 arrest in Ishikawa cells,
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but only at the highest drug concentration (20 mM, p=0.003). Metformin does not
appear to affect cell cycle progression in Hec1A cells.
3.4. Effect of Metformin on In Vivo Tumor Growth
Following intraperitoneal injection of EC cell lines into athymic nude mice and
stratification into metformin-treated and vehicle-treated groups mice were observed
for symptoms including massive ascites, hunched posture, or abnormal gait
indicating impending death.

Each cage (housing 5 mice) consistently drank 25

mL/day regardless of metformin water or control water throughout the course of the
study. When at least one mouse in each group was noted to display any moribund
symptoms, all mice in the group were euthanized. The time to the development of
moribund symptoms was 50 days for the Hec1A group, 64 days for the Ishikawa
group, and 29 days for the MecPK group. At the conclusion, all 20 (100%) mice
injected with Hec1A, all 20 (100%) mice injected with Ishikawa, and 17 of 20 mice
(85%) injected with MecPK developed intraperitoneal tumors. Table 1 provides a
summary of results. Prior to necropsy, all mice were weighed. Mean body weights
for control and metformin-treated mice were not significantly different for any of the
cell lines (Table 1).

Following weight determination and collection of serum,

necropsy was performed and all visible tumors were collected from all peritoneal
surfaces. Metformin-treated mice had a significantly decreased mean tumor weight
compared to untreated mice (0.22 g vs. 0.40 g, p=0.002) in the Hec1A group and in
the MecPK group (0.722 g vs. 1.372 g, p=0.024).

In contrast, there was no

difference in mean tumor weights between metformin-treated and untreated mice
(0.87 g vs. 1.12 g, p=0.337) in the Ishikawa group. As markers for toxicity, we also
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evaluated and compared mean mouse weights at the time of necropsy and serum
liver enzyme levels. Mean mouse weights were not significantly different between
groups (Table 1). Also, metformin treatment did not adversely affect serum liver
enzyme levels (Table 1).

Cell
Line

Hec1A

Ishikawa

MecPK

Mice
(n)

20

20

20

Developed
Tumor
n(%)

20 (100%)

20 (100%)

17 (85%)

Time to
Moribund
(days)

50

64

29

Mean Mouse
Wt (g)

Mean Tumor Wt
(g)

Mean Serum
ALT (U/L)

Control: 27.01

Control: 0.395

Control: 17.5

Metformin: 25.97

Metformin: 0.216

Metformin: 22.0

p=0.281

p=0.002

p=0.228

Control: 26.28

Control: 1.119

Control: 30.0

Metformin: 26.24

Metformin: 0.868

Metformin: 37.7

p=0.971

p=0.337

p=0.616

Control: 26.41

Control: 1.372

Control: 13.7

Metformin: 24.95

Metformin: 0.722

Metformin: 17.0

p=0.420

p=0.024

p=0.059

Table 2. In Vivo effect of metformin on mean tumor weight in nude mouse
xenografts. Metformin treatment resulted in significant reductions in mean tumor
weights in Hec1A- and MecPK-inoculated mice.
3.5. Effect of Metformin on Tissue Expression of pS6rp and Ki-67
Immunohistochemical analysis of tumor pS6rp expression as a downstream
marker of PI3K/AKT pathway signaling and Ki-67 staining as a marker for
proliferation was carried out. The mean percentage of cells staining positive for Ki67 was not significantly different between metformin-treated and vehicle controltreated groups for either Hec1A or Ishikawa tumor tissues (Figure 5A). However,
consistent with the in vitro results, expression of pS6rp was significantly decreased
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in metformin-treated Hec1A tumor tissue compared to vehicle control-treated tissue
(mean IHC score 4.9 vs. 7.8, p=0.009) – (Figure 5B). In contrast, there was no
significant difference in the expression of pS6rp in metformin-treated Ishikawa tumor
tissue compared to vehicle control-treated tissue (mean IHC score 5.8 vs. 5.3,
p=0.642) – (Figure 5B).

A

B

Figure 5. Immunohistochemical analysis of xenograft tumors - A) There
were no differences in the percentage of cells staining positive for Ki-67
between metformin-treated and vehicle control-treated groups for either Hec1A
or Ishikawa tumor tissues. B) Expression of pS6rp was significantly decreased
in metformin-treated Hec1A tumor tissue compared to vehicle control-treated
tissue

3.6. Expression of PTEN Does Not Alter Response to Metformin
Transfection of MecPK cells with plasmid pIRES2 containing PTEN gene insert
resulted in stable expression of PTEN. The functionality of PTEN was confirmed by
evaluating the activation of downstream signaling pathways; pS6rp expression was
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down-regulated in PTEN expressing cells as compared to MecPK cells transfected
with plasmid alone (Figure 6A).

Following metformin treatment for 48 hours at

varying concentrations, there was no difference in relative cell viability when
comparing parental MecPK transfected with pIRES2-vector alone to MecPK cells
transfected with pIRES2-EGFP-PTEN stably expressing PTEN (Figure 6B). The
mean IC50 value for control MecPK cells was 3.31 mM and for MecPK cells
expressing PTEN it was 3.00 mM.

A

PTEN
pS6rp
βActin

B

pIRES2 pIRES2- PTEN Vector

Figure 6. Re-expression of PTEN in MecPK cells and dose-response to metformin
treatment - A) Transfection of MecPK cells with plasmid pIRES2-EGFP-PTEN insert
demonstrated expression of PTEN which resulted in down-regulation of downstream
read-out pS6rp compared to MecPK cells transfected with pIRES2-EGFP-vector alone.
B) Following metformin treatment for 48 h, there were no significant differences relative
cell viability between parental MecPK and cells expressing PTEN. These data represent
three independent experiments performed in triplicate. Error bars indicate +/- SEM.

49

3.7. Transient Silencing of Mutant K-Ras Decreases Sensitivity to Metformin
Treatment
Transient silencing of K-Ras in MecPK cells using targeted siRNA results in a
significantly decreased expression of total K-Ras when compared to cells treated
with non-target siRNA (control) (Figure 7A). In both groups, metformin treatment at
5 – 20 mM resulted in significant decreases in relative cell survival compared to
PBS-treated controls indicating that K-Ras silencing alone is not sufficient to
abrogate metformin’s effect on proliferation. However, cells with transiently silenced
K-Ras demonstrated significantly decreased sensitivity to metformin treatment (5 –
20 mM) compared to parental MecPK cells transfected with non-targeted siRNA
(Figure 7B).

A

B

Total K-Ras

Figure 7. Transient silencing of K-Ras in MecPK cells and dose-response to
metformin treatment - A) Transient silencing of K-Ras in MecPK cells using targeted
siRNA results in decreased total K-Ras expression. B) Following treatment for 48 h,
MecPK cells with transiently silenced K-Ras displayed decreased sensitivity to metformin
at 5 – 20 mM compared to parental MecPK cells transfected with non-targeted siRNA
(negative control). These data represent three independent experiments performed in
triplicate. Error bars indicate +/- SEM.
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3.8. Expression of Mutant K-Ras Increases Sensitivity to Metformin
Treatment
Transfection of Ishikawa cells with plasmid pMEV containing an oncogenic
mutant K-RasG12D insert resulted in a 4-fold increased expression of K-Ras at the
mRNA level when compared to Ishikawa cells transfected with pMEV vector alone
(Figure 8A). Following metformin treatment for 48 hours at varying concentrations,
cells expressing the mutant K-Ras had slightly increased sensitivity to metformin
compared to controls expressing wild-type K-Ras. IC50 values for the controls could
not be calculated based on concentrations used and the dose-response curve.
However, a metformin IC50 of 57.7 mM was calculated in Ishikawa cells expressing
mutant K-Ras (Figure 8B).

A

B

Figure 8. Expression of mutant K-RasG12D in Ishikawa cells and doseresponse to metformin treatment - A) Transfection of Ishikawa cells with
plasmid pMEV containing an oncogenic mutant K-RasG12D insert resulted in
a 4-fold increased expression of K-Ras at the mRNA level. B) Cells
expressing the mutant K-Ras had slightly increased sensitivity to metformin
compared to controls expressing wild-type K-Ras following 48h of treatment.
These data represent three independent experiments performed in triplicate.
Error bars indicate +/- SEM.
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3.9. Metformin Treatment Causes Mislocalization of K-Ras to the Cytoplasm
Confocal microscopy analysis was used to evaluate the localization of GFP-KRasG12V (Figure 9A) and GFP-H-RasG12V (Figure 9B) in MDCK cells in response
to increasing concentrations of metformin over 48 hours.

A

B

Figure 9. Effect of metformin (0.001 – 2 mM) on K-Ras localization analyzed by
confocal microscopy in Madin-Darby Canine Kidney (MDCK) cells - Expressing A)
GFP-labeled oncogenic K-RasG12V mutant and B) GFP-labeled oncogenic H-RasG12V
mutant.
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MDCK cells expressing GFP-K-RasG12V treated with metformin showed a
concentration-dependent translocation of K-Ras from the plasma membrane to the
cytoplasm, with an IC50 of 357 uM (Figure 10).

In contrast, in MDCK cells

expressing GFP-H-RasG12V, translocation of H-Ras from the plasma membrane to
the cytoplasm was less sensitive to metformin treatment, with an IC50 of 2.76 mM
(Figure 10). The advantage to using MDCK cells for this screening assay is that
they grow in confluent monolayers allowing for clear imaging and analysis.

Figure 10. Quantitative analysis of K-Ras and H-Ras localization following
metformin treatment using confocal microscopy. Treatment with metformin
resulted in a concentration-dependent translocation of K-Ras from the plasma
membrane to the cytoplasm, with a mean IC50 of 357 uM. These data
represent three independent experiments performed in triplicate. Error bars
indicate +/- SEM.
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We attempted to validate the results observed above in human endometrial
cancer (Hec1A) cells transfected with GFP-K-RasG12V (Figure 11). However, as
Hec1A cells have a tendency to grow in multiple layers when confluent, this made
quantification of intracellular localization using confocal microscopy unreliable.

Figure 11. Effect of metformin (0.1 – 5 mM) on K-Ras localization
analyzed by confocal microscopy in Hec1A cells expressing GFPlabeled oncogenic K-RasG12V mutant.

As a result, metformin’s effect on K-Ras localization was validated using in
Hec1A cells by subcellular fractionation studies and western immunoblot analysis.
To confirm purity of cellular fractions and equal loading of proteins, membranes were
incubated with antibodies directed against Na+/K+ ATPase (membrane-specific) and
total AKT (cytoplasm-specific) – (Figure 12A).

Metformin treatment caused a

concentration-dependent mislocalization of K-Ras from the plasma membrane to the
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cytoplasm with significance achieved at 1 and 5 mM of metformin (p=0.006 and
p<0.001) compared to PBS treatment (Figure 12B).

Figure 12. Hec1A subcellular fractionation following metformin
treatment - A) Na/K ATPase served as the membrane-specific
antibody and Total AKT served as the cytoplasm-specific antibody to
confirm purity of fractions. B) Metformin treatment induced a
concentration-dependent translocation of K-Ras from the plasma
membrane to the cytoplasm with significance achieved at 1 and 5
mM (p=0.029 and p<0.0001) compared to PBS treatment. These
data represent three independent experiments performed in triplicate.
Error bars indicate +/- SEM.
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3.10. The Effect of Metformin on K-Ras Localization is AMPK-Independent
Treatment of Hec1A cells with AICAR resulted in a concentration-dependent
mislocalization of K-Ras from the plasma membrane to the cytoplasm with
significance at 0.1 mM (p=0.0002) and 1 mM (p<0.0001) – Figure 13A and 13B. To
evaluate whether this effect is AMPK-dependent, we pretreated cells with
Compound C 10 uM for 1 hour prior to and during treatment with metformin or
AICAR. The addition of Compound C did not result in a significant difference in KRas mislocalization following treatment with metformin 5 mM (p=0.257) or with
AICAR 1 mM (p=0.946) – Figure 14B.

A

B

Figure 13. A) Hec1A subcellular fractionation following 48 h of
metformin or AICAR treatment. B) AICAR also induced a
concentration-dependent translocation of K-Ras from the plasma
membrane to the cytoplasm compared to PBS treatment. These
data represent two independent experiments performed in
triplicate. Error bars indicate +/- SEM.
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To confirm whether compound C had an effect on AMPK activation over this
extended course of treatment, western immunoblotting was performed during which
membranes were incubated with antibody directed against phosphorylated AMPKα
(Thr172) (pAMPKα).

Cells treated with Compound C exhibited decreased

expression of pAMPKα at both the membrane and in the cytoplasm when compared
to cells that were not treated with Compound C (Figure 14A). This indicates that the
effects of metformin and AICAR on K-Ras mislocalization are AMPK independent.

A

B

Figure 14. Hec1A subcellular fractionation following 48 h of metformin or
AICAR treatment with and without Compound C – A) Treatment with
Compound C resulted in decreased expression of pAMPKα. B) Pre-treatment
with Compound C 10 uM for 1 hour followed by co-treatment with either
Metformin 5 mM or AICAR 1 mM did not alter the effect of these drugs on K-Ras
localization. These data represent two independent experiments performed in
triplicate. Error bars indicate +/- SEM. D – DMSO; M – Metformin 5 mM; A –
AICAR 1 mM; C – Compound C 10 uM

57

3.11. The Combination of Metformin with PI3K Pathway Inhibitors Results
in an Additive Decrease in Cell Viability
The relative cell viability of MecPK cells was determined by MTT assays after 48
hours of the following treatments: RAD001 10 nM, BEZ235 100 nM, metformin 5
mM, AZD6244 10uM, and the combinations of RAD001 10 nM plus metformin 5
mM, BEZ235 100 nM plus metformin 5 mM, and AZD6244 10 uM plus metformin 5
mM. The combination of RAD001 with metformin produced a significant decrease in
relative cell viability than that achieved with either RAD001 alone (p=0.008) or
metformin alone (p=0.035) – Figure 15A. Similarly, the combination of BEZ235 with
metformin produced a significant decrease in relative cell viability than that achieved
with either BEZ235 alone (p=0.003) or metformin alone (p=0.029) – Figure 15B. In
contrast, the combination of AZD6244 with metformin did result in a significant
decrease in relative cell viability than that achieved with AZD6244 alone (p=0.201) or
metformin alone (p=0.661) – Figure 15C.
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A

B

C

Figure 15. MTT assays representing treatment of MecPK cells with either: A)
RAD001 10nM or metformin 5mM alone or in combination; B) BEZ235 100nM or
metformin 5mM alone or in combination; and C) AZD6244 10uM or metformin
5mM alone or in combination. For both RAD001 and BEZ235, combination
treatment with metformin resulted in decreased relative cell viability than with
either agent alone. In contrast, combination treatment with the MEK inhibitor
AZD6244 and metformin did not result in a greater decrease in relative cell
viability than with either agent alone. These data represent three independent
experiments performed in triplicate. Error bars indicate +/- SEM.

59

The expression of downstream proteins in the PI3K and Ras-MAPK pathways
were evaluated by western immunoblots following treatment with DMSO, metformin
5 mM, RAD001 10 nM, AZD6244 6 uM, or the combinations of RAD001 10 nM plus
metformin 5 mM or RAD001 10 nM plus AZD6244 6 uM.

Treatments and

immunoblots were performed on MecPK cells and expressed in Figure 16.
Metformin treatment increased the expression of pAMPKα and decreased the
expression of pAKT, pS6rp, and pERK1/2. These effects were more prominent in
cells treated with the combination of RAD001 and metformin.

Treatment with

AZD6244 increased the expression of pAKT and pS6rp. Following the addition of
RAD001 to AZD6244, pS6rp expression decreased, but pAKT remained
overexpressed compared to DMSO treated cells.

Figure 16. MecPK cells treated for 48h with metformin 5
mM alone, RAD001 10 nM alone, AZD6244 6 uM alone, or
combinations of RAD001 with either metformin or
AZD6244. Metformin treatment increased the expression of
pAMPKα and decreased the expression of pAKT, pS6rp,
and pERK1/2. These effects were more prominent in cells
treated with the combination of RAD001 and metformin.
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Similarly, addition of metformin 5 mM to BEZ235 100 nM resulted in decreased
expression of pS6rp and pAKT (Figure 17). BEZ235 alone does not appear to affect
MAPK signaling (pERK1/2 expression).

However, metformin alone and in

combination with BEZ235 treatment decreases pERK1/2 expression.

Figure 17. Addition of metformin to BEZ235 results in decreased
phosphorylation of S6rp and AKT. BEZ235 alone does not appear
to affect pERK1/2 expression (Ras-MAPK pathway). However,
metformin alone and in combination with BEZ235 treatment
decreases Ras-MAPK signaling.
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4. Discussion
The chemopreventive and antineoplastic effects of metformin are currently being
evaluated for the treatment of a variety of cancers. Although its mechanism of
action is not fully understood, metformin is thought to inhibit cell proliferation locally
via activation of the AMPK signaling pathway, which counteracts the growthpromoting effects of PI3K pathway hyperactivity. Activation of the PI3K pathway, as
a consequence of the inactivating mutation of the PTEN tumor suppressor gene, is a
commonly observed mutation in type I endometrial cancer.

With this in mind, we

set out to evaluate the in vitro and in vivo effects of metformin on endometrial cancer
growth based on PTEN mutational status. While we demonstrated that metformin is
a potent inhibitor of cell proliferation and inducer of apoptosis in vitro and of tumor
growth in vivo; surprisingly its activity appears to be more robust in endometrial
cancer cell lines that possess an activating K-Ras mutation as compared to those
lacking PTEN. These preliminary findings led us to further evaluate the effect of
metformin on Ras signaling and intracellular localization.
First, we confirmed metformin activates AMPK in a concentration-dependent
manner in all endometrial cancer cell lines used.

A decrease in PI3K pathway

signaling was observed in Hec1A and MecPK cells, both of which harbor activating
mutations in K-Ras, but not in Ishikawa cells which express wild-type K-Ras.
Furthermore, we demonstrated that pERK1/2 expression was decreased in a
concentration-dependent manner only in Hec1A and MecPK cells and observed that
metformin is a potent inducer of apoptosis in both of these cell lines. These in vitro
findings were further supported by our xenograft model which demonstrated reduced
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tumor growth in metformin-treated mice that had been inoculated with Hec1A or
MecPK, but not with Ishikawa.
Based on these data, a few other observations can be made. Metformin can
produce anti-proliferative effects in vitro indicating that it acts directly on endometrial
cancer cells and is not solely reliant on reducing serum insulin levels.

It is

noteworthy that the effects of metformin on in vivo tumor growth mirrored the effects
seen in vitro. Certainly, this is not to minimize the proposed indirect mechanism of
action of metformin, but, rather, indicates that the anti-neoplastic actions of
metformin on endometrial cancer likely represent a combination of both direct and
indirect effects. Importantly, all endometrial cancer cell lines included in this study
expressed OCT1.

OCT1 or OCT3 have previously been demonstrated to be

essential for metformin entry into cells. Indeed, cells that do not express OCT1 are
immune to the direct effects of metformin (42). In a recent study evaluating the
relevance of the OCT1 transporter to the antineoplastic effect of biguanides in
epithelial ovarian carcinoma (EOC), siRNA knockdown of OCT1 reduced the
sensitivity of EOC cells and abrogated the activation of AMPK in response to
metformin in a concentration-dependent manner (42).
A frequently cited criticism of preclinical studies involving metformin is that
concentrations used in vitro are higher than therapeutic serum concentrations
achieved in clinical practice. Specifically, across various cancer cell lines, IC50s
achieved with metformin are in the millimolar range (1-10 mM), while the therapeutic
serum concentration of metformin in diabetic patients (treated with 500-2000 mg/day
orally) is approximately 20 mcmol/mL. Although this appears to be quite a
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difference, there are a few possible explanations. First, the media used in tissue
culture often contains supraphysiologic glucose levels that may limit the response to
metformin (99).

Also, metformin has been shown to accumulate in tissues at

concentrations significantly higher than in the serum in both mice (38) and human
studies (39). Using a formula for dose translation from human to mouse based on
body surface area (BSA) (100), a standard human metformin dose of 24.3 mg/kg
daily (based on 850 mg twice daily by mouth in a 70 kg human) translates to 299.7
mg/kg daily in a mouse. In our metformin xenograft study, each mouse was treated
daily with 5 mg of metformin dissolved in drinking water. Assuming an average
mouse weight of 0.02 kg, each mouse received 250 mg/kg of metformin daily which
is similar, and certainly not higher, to what is expected based on human equivalency
dosing.

Furthermore, in our xenograft model, metformin did not induce weight

changes or elevations in serum liver enzymes that would indicate toxicity.
While our preliminary data provided some insight into specific genetic alterations
that may make a cell more sensitive to metformin treatment, we next sought to
evaluate if metformin’s antiproliferative effects are mediated specifically by opposing
the Ras-MAPK or PI3K signaling pathways, or both. Furthermore, we sought to
determine if the mechanism of inhibition is something other than up-regulation of
AMPK by disruption of the energy homeostasis of the cell. First, to investigate the
role of PTEN expression on the activity of metformin, we stably transfected and reexpressed PTEN in MecPK cells and compared their response to metformin with
MecPK cells transfected with vector alone. As you may recall, MecPK cells are
derived from a transgenic mouse harboring a K-RasG12D mutation and
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homozygous loss of PTEN function. In this cell line, we demonstrated that PTEN reexpression does not alter response to metformin. That is, MecPK cells expressing
PTEN were not more or less sensitive to metformin treatment by cell viability assays
when compared to control MecPK cells with loss of PTEN. In contrast, when K-Ras
is transiently silenced in MecPK cells using siRNA, we demonstrated that these cells
are less sensitive to metformin at higher concentrations than parental controls.
These observations indicate that metformin may act to disrupt signaling of the RasMAPK pathway, a well-known pro-survival pathway that is frequently mutated in a
variety of tumor types. The next question was: How?
As described above, Ras signaling requires a series of post-translational
modifications with the ultimate goal of facilitating transport of the Ras protein to the
plasma membrane where, in response to growth signals, it is activated by GEFs and
can interact with effector molecules to propagate the growth signal. Mutations in
Ras lead to constitutive activation and persistent signaling through effector pathways
which can ultimately lead to malignant transformation. We have already reviewed
the extensive cross-talk between the Ras and PI3K pathways and the importance of
the latter in Ras-dependent tumor initiation and maintenance. This process is further
accentuated by frequently encountered activating mutations in the PI3K pathway,
such as PIK3CA mutations or PTEN loss of function. Interestingly, while mutations
in the Ras and PI3K pathways are mutually exclusive in some tumor types such as
breast cancer, they frequently coexist in endometrial and colon cancer (48, 81, 85,
101). Given our preliminary results demonstrating that metformin appeared to have
the greatest inhibitory effect on cellular proliferation and in vivo tumor growth in
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endometrial cancer cell lines harboring activating K-Ras mutations regardless of
PTEN expression status; we hypothesized that metformin may have a direct effect
on K-Ras localization and trafficking to the plasma membrane, leading to decreased
activation and subsequent decreased signaling through effector pathways.
Following a series of experiments evaluating the subcellular localization of Ras in
response to metformin treatment, we demonstrated that metformin causes
mislocalization of Ras from the plasma membrane to the cytoplasmic compartment.
This effect appears to be specific to the K-Ras isoform as mislocalization of H-Ras to
the cytoplasm required much higher metformin concentrations. This indicates that
metformin acts to disrupt transport of Ras proteins, in other words the “second
signal,” rather than altering or inhibiting the series of post-translational modifications
required for all newly synthesized Ras proteins to localize to the Golgi.
The interaction between metformin and the Ras-MAPK signaling pathway have
gained increasing attention recently.

Metformin has been shown to inhibit Ras-

induced reactive oxygen species production and DNA damage; a mechanism that
may contribute to its effects as a cancer preventive agent (102). In breast cancer,
metformin has been demonstrated to induce cancer cell apoptosis by targeting ERK
signaling (103). However, what has yet to be reported is the mechanism by which
metformin disrupts Ras signaling. Our data suggests that metformin may disrupt
plasma membrane localization of K-Ras and hence its signaling. As K-Ras and HRas are transported to the plasma membrane through different mechanisms,
metformin, through an unclear mechanism, interferes specifically with K-Ras
transport. This may possibly occur through disruption of electrostatic interactions
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between K-Ras and the plasma membrane or through activation of a farnesylelectrostatic switch. In the latter, phosphorylation of the polybasic domain of K-Ras
by protein kinase C (PKC), or potentially by AMPK, reduces the net positive charge,
causing K-Ras to lose affinity to the plasma membrane and to accumulate in
endomembranes (57). Interestingly, it has been demonstrated that when K-Ras has
an activating mutation, translocation to endomembranes is associated with
apoptosis (104).

This may further explain our findings that metformin potently

induces apoptosis in endometrial cancer cell lines harboring an activating K-Ras
mutation. To determine if these effects are related to metformin’s ability to activate
AMPK, we performed a series of experiments using AICAR, an AMP analog that
potently activates AMPK, and Compound C, an inhibitor of AMPK.

We

demonstrated that similar to metformin, AICAR causes concentration-dependent
mislocalization of K-Ras to the cytoplasm. However, treatment with Compound C
and subsequent inhibition of AMPK did not abrogate the effects of either metformin
or AICAR on K-Ras intracellular localization. This indicates that metformin’s effects
on K-Ras localization are AMPK-independent.

Further studies are necessary to

investigate the precise mechanism by which metformin causes mislocalization of KRas. It has been demonstrated that interference of electrostatic interactions by a
cationic amphiphilic drug (chlorpromazine) reduces the association of K-RasG12V
(but not H-Ras) with the plasma membrane, leading to accumulation in endosomal
or mitochondrial membranes resulting in growth inhibition and apoptosis (105). As
metformin exists primarily as a hydrophilic cationic molecule at physiological pH
values and has previously been demonstrated to increase the activity of atypical
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PKC (34, 106), this may be a possible explanation for its effects on K-Ras
mislocalization.
It is also intriguing to speculate on the role of metformin on cancer cell
metabolism. Since the 1920s, it has been observed that cancer cells shift from
mitochondrial oxidative phosphorylation and rely on glycolysis to generate energy
needed for maintenance of cellular processes and growth, a phenomenon known as
the “Warburg effect” (107).

Most cells in a multicellular organism under normal

physiologic conditions rely on mitochondrial oxidative phosphorylation as the energy
yield in the form of ATP (36 mol per glucose molecule) is significantly greater than
with glycolysis (2 mol of ATP per glucose molecule). As such, these cells reserve
glycolysis for conditions of oxygen deprivation allowing cells to continue ATP
production.

Why is it then that cancer cells preferentially utilize a less efficient

metabolic pathway? For one, many cancer cells in solid tumors are in a chronic
hypoxic environment demanding that they use anaerobic glycolysis as a means to
generate energy.

However, even when oxygen is plentiful, cancer cells still

preferentially utilize aerobic glycolysis. The reason for this is a shift in their priorities.
Cancer cells want to divide rapidly which requires that they replicate all of their
cellular contents, a process that requires significantly more resources (such as
NADPH and acetyl-coenzyme A) than just ATP alone (107). As such, cancer cells
preferentially metabolize glucose and glutamine to generate the precursors needed
for fatty acid and amino acid synthesis. Recent work has demonstrated that Rasdependent transformation results in an early switch to aerobic glycolysis (108, 109).
Despite the switch to glycolysis, some cancer cells retain the capacity for oxidative
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phosphorylation, particularly when nutrients are low (110). Metformin is known to
inhibit oxygen consumption and mitochondrial complex I (111, 112). This inhibition
of oxidative phosphorylation may lead to ATP depletion and an energy crisis with the
end result of apoptosis. This may provide another explanation for the induction of
apoptosis that we demonstrated following metformin treatment in K-Ras mutant cell
lines.
Our observations have important clinical implications in endometrial cancer,
particularly endometrioid-type, as up to 26% harbor activating K-ras mutations and
up to 83% of cases have PTEN loss with subsequent PI3K hyperactivation. With the
recent interest in personalizing cancer care, several targeted strategies have been
developed and evaluated for the treatment of endometrial carcinoma (113).
Unfortunately, some combination therapies involving PI3K pathway inhibitors with
MEK inhibitors have proven to be toxic in Phase I studies making their development
into feasible treatment strategies uncertain. To evaluate the role of metformin, as a
possible Ras-MAPK pathway inhibitor, we combined it with either RAD001 (an
mTORC1 inhibitor) or BEZ235 (a pan-PI3K/mTOR inhibitor) and demonstrated
decreased relative cell viability on proliferation assays with the combinations than
with either of the agents alone. In contrast, when metformin was combined with a
MEK inhibitor, AZD6244, there was no additive benefit over either agent alone. This
indicates that metformin may have therapeutic utility when combined with inhibitors
of the PI3K pathway. In an on-going single-arm, open-label phase II trial at M.D.
Anderson Cancer Center of RAD001 (10 mg daily) in combination with letrozole (2.5
mg daily), 9 of the 35 evaluable patients on trial were also using metformin (4 were
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on metformin prior to study entry for diabetes, 5 started metformin while on trial for
RAD001-induced hyperglycemia). Interestingly, metformin users had a substantially
improved clinical benefit rate (CBR) and objective response rate (ORR) (78% and
44%) compared to the 26 metformin non-users on the study, with a CBR and ORR
of 39% and 12% in that group. Of the four complete responders on trial, three
occurred in the metformin group. Toxicities in patients taking metformin were not
significantly different to those not taking metformin.
Metformin may also be combined with cytotoxic agents as a potential
chemosensitizer.

It was recently demonstrated that metformin potentiates the

effects of paclitaxel in endometrial cancer cells through modulation of the mTOR
pathway and cell cycle progression (96).

These effects may be due in part to

metformin’s ability to down-regulate glyoxalase I (GloI) expression, an enzyme
involved in glycometabolism that is abundant in tumor tissues and has been
associated with chemoresistance (114).
Furthermore, our observations may also provide a rationale for use of metformin
in several other cancer types that have a high incidence of K-Ras mutations such as
pancreatic and colorectal cancer.

Indeed, in several retrospective studies,

metformin use has been associated with a survival advantage in patients with
pancreatic cancer (115) and colorectal cancer (116). However, prospective studies
are needed to validate these findings.
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5. Conclusions
In conclusion, metformin significantly inhibits cell proliferation, induces apoptosis,
and decreases tumor growth in preclinical models of endometrial cancer. Metformin
appears to be most effective against mutant K-Ras endometrial cancer cells.
Metformin inhibits K-Ras signaling by inducing mislocalization of K-Ras from the
plasma membrane to the cytoplasm through a process that appears to be AMPKindependent.

Metformin’s effects on K-Ras may provide added benefit when

combined with other targeted agents, notably mTOR inhibitors, to improve
responses. This data provides preclinical support for clinical trials using metformin
in combination with PI3K targeted agents, specifically in tumors harboring activating
K-Ras mutations.
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